广誉远中药股份有限公司 GuangYuYuan Chinese Herbal Medicine Co., Ltd. 会议资料 二〇二五年六月二十四日 中国·山西·太原 东大会会议资料 广誉远中药股份有限公司 2024 年年度股 目 录 十九、公司关于修订《广誉远中药股份有限公司担保管理办法（试行）》的议案 ..... 141 广誉远中药股份有限公司 2024 年年度股东大会会议资料 广誉远中药股份有限公司 为维护全体股东的合法权益，确保年度股东大会的正常秩序和议事效率，保证本次 股东大会的顺利召开，根据《公司法》、中国证监会《上市公司股东大会规则》 《公司章 程》和《股东大会议事规则》等规定，特制定如下会议须知： 一、出席本次现场股东大会的股东及股东代理人，应在会议开始前半小时到达会议 地点，携带相关证件办理会议登记手续，有序落座，会议开始后，登记终止，不接待迟 到人员。 二、会议安排有交流环节，股东要求发言时，须经会议主持人同意。股东不得随意 打断会议报告人的报告或其他股东的发言。 三、股东发言时，应首先报告姓名或代表的股东，为了保证会议效率，发言应简洁 明了，发言主题应与本次会议议题相关。 四、主持人有权 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 MACD金叉信号形成，这些股涨势不错！ 理 围绕增长考核业绩，围绕投资者关系管理等考核经营质量，围绕市场份额和品牌影响力评价企业价 值，以提升公司整体基本面优势和投资价值为宗旨。2025年经营指标未公开披露，公司仍以保持增长为 原则，制定内部分产品和分事业部的考核指标，对标一流，不断精进管理，赋能影响，综合提升公司市 场竞争力，争取早日实现营销历史性突破和行业地位提升。 对于央国企关于市值管理的相关文件，公 司已学习并非常重视，作为中证A500成份股，已按照要求制定了《市值管理制度》，公司将贯彻执 行，从提升经营业绩、改善经营质量、常态化业绩说明会、加强日常与资本市场沟通、做好舆情管理和 日常中小投资者沟通交流等角度持续改善，在公司股价出现异常波动时及时启动应急机制，充分重视市 值指标的动态监控。需要履行信息披露义务的相关事项，还请关注公司公告。 淳厚欣享A（基金代码：009931）是淳厚基金旗下的一只混合型基金，成立于2020年9月15日。现任基 金经理由陈文和杨煜城共同担任，其中陈文自2020年9月15日起任职，总管理规模达17.26亿元。该基金 通过对企 ...

Group 1 - The core viewpoint of the collaboration between Guangyuyuan and Zhongkang Technology is to enhance brand value, market insights, and product innovation in the high-end traditional Chinese medicine sector [1][3] - The meeting emphasized the importance of cultural empowerment and data-driven strategies to position Guangyuyuan among the top tier of high-end traditional Chinese medicine brands [1][3] - The collaboration aims to leverage Zhongkang Technology's strengths in data analysis and resource integration to optimize product distribution and enhance operational efficiency [3][4] Group 2 - The traditional Chinese medicine market is shifting towards rational and quality-focused consumption, creating opportunities for high-quality brands like Guangyuyuan [3] - Guangyuyuan, with nearly 500 years of history, aims to reconstruct its brand value by focusing on cultural heritage and modern health needs [3][4] - The partnership will explore innovative expressions of traditional Chinese medicine culture, enhancing consumer awareness of heritage craftsmanship [4]

Company Performance - Guangyuyuan achieved an operating income of 1.22 billion yuan and a net profit attributable to shareholders of 74.45 million yuan for the year 2024 [1] - In Q1 2025, the company reported an operating income of 417 million yuan, a year-on-year increase of 21.48%, and a net profit of 63.58 million yuan, up 53.94% year-on-year [1] Industry Overview - The pharmaceutical manufacturing industry in China has shown signs of transformation driven by policy changes and market demand, with total operating income for 2024 at 25,298.5 billion yuan, remaining stable compared to 2023 [2] - The total profit for the pharmaceutical manufacturing industry in 2024 was 342.07 billion yuan, reflecting a year-on-year decline of 1.1%, although the rate of decline has slowed [2] - The traditional Chinese medicine sector is recovering growth due to government support and external factors such as an aging population and increased health demands [2] R&D and Innovation - Guangyuyuan has a history of 484 years and is recognized as a "Chinese Time-honored Brand," with key products included in national and provincial intangible cultural heritage lists [3] - The company increased its R&D expenditure to 38.59 million yuan in 2024, a 22.98% increase from the previous year, focusing on key products to enhance competitiveness [3] - Guangyuyuan is committed to a dual-driven development model of inheritance and innovation, collaborating with research institutions to create profitable research outcomes [3] Marketing Strategy - There is a growing demand for traditional Chinese medicine for health maintenance, with Guangyuyuan's products targeting specific consumer groups, indicating potential growth in the outpatient market [4] - The company has deepened strategic partnerships with top-tier chains and expanded its marketing channels, leading to significant growth in sales revenue [4] - Guangyuyuan has established a digital economy division to enhance online sales channels, adapting to new consumer trends and creating a strong competitive advantage [4]

随着我国心脑血管疾病持续高发，在政策支持中医药产业发展背景下，由盛唐流传至今的温通开窍名药——苏合香丸， 凭借临床循证研究与现代工艺革新，在心脑血管防治领域掀起新的浪潮。 综合米内网与中康CMH数据，苏合香丸在城市公立医院端销售额从2 0 2 0年的4 2 0 8万元，增长至2 0 2 3年的5 . 5 8亿元，城 市药店零售端则由2 3 2万元增至2 0 2 4年的8 2 0 0万元；其中，雷允上苏合香丸在 该品类处于优势地位： 2 0 2 4上半年，雷 允上苏合香丸在中国城市公立医疗机构的市场份额约为7 5 . 1 5%， 2 0 2 4年在零售端增幅高达2 3 6%， 增速明显高于片仔 癀、龟龄集等经典名方。 从临床突破到零售表现，苏合香丸的崛起轨迹颇具启示意义。当政策支持与传统名方升级形成共振，苏合香丸的爆发式 增长，或许正是中医药守正创新的一个缩影。 雷允上引领苏合香丸破圈 随着中医药产业获得政策的重视，市场规模也不断扩容。以整个心脑血管品类中成药销售规模为例，据中康CMH数据， 2 0 1 7年销售额仅为5 2 . 1 6亿元，至2 0 2 4年便增长至1 0 0 . 8 3亿元，近乎翻了一倍。心 ...